- facial swelling, lip, mouth, tongue, or throat inflammation, difficulty breathing,
-severe dizziness or fainting,
-abnormally fast or irregular heartbeats.
In decreasing order of frequency, side effects may include:
-Frequent (affecting between 1 and 10 out of every 100 patients treated): headache, dizziness, vertigo, numbness, visual disturbances, tinnitus (sensation of noise in the ears), mild dizziness due to low blood pressure, cough, difficulty breathing, gastrointestinal disturbances (nausea, vomiting, abdominal pain, altered taste, dry mouth, dyspepsia or difficulty digesting, diarrhea, constipation), allergic reactions (such as skin rashes, itching), muscle cramps, feeling tired, low potassium levels in the blood.
-Less frequent (affecting between 1 and 10 out of every 1,000 patients treated): mood changes, sleep disturbances, bronchospasm (chest tightness, wheezing, and difficulty breathing), angioedema (symptoms such as wheezing, facial or tongue inflammation), urticaria, purpura (red spots on the skin), kidney problems, impotence, sweating, depression, low sodium levels in the blood that may cause dehydration and low blood pressure, impotence (inability to achieve or maintain an erection).
Rare (may affect up to 1 in 1,000 people): worsening of psoriasis, decreased or absent diuresis, facial flushing, acute renal failure, low chloride levels in the blood, low magnesium levels in the blood.
Concentrated urine, feeling unwell (nausea) or vomiting, muscle cramps, confusion, and seizures. These symptoms may be a condition called SIADH (inadequate secretion of antidiuretic hormone).
-Very rare (affecting fewer than 1 in 10,000 patients treated): confusion, cardiovascular disorders (irregular heartbeat, angina, myocardial infarction), eosinophilic pneumonia (a rare type of pneumonia), rhinitis (stuffy or runny nose), severe skin changes such as erythema multiforme. If you have systemic lupus erythematosus (a type of collagen disease), it may worsen. Cases of photosensitivity reactions (skin changes) after exposure to sunlight or artificial UVA radiation have also been described.
-Frequency not known (cannot be estimated from available data):fainting, irregular heartbeat with life-threatening risk (Torsade de Pointes),abnormal electrocardiogram, elevated liver enzymes.Change in color, numbness, and pain in the fingers or toes (Raynaud's disease).Decreased vision or eye pain due to high pressure [possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma].
Abnormal blood test results, kidney, liver, or pancreas problems, and changes in blood test results may occur. Your doctor may need to prescribe blood tests to monitor your condition.
In cases of liver failure (liver problems), there is a possibility of developing hepatic encephalopathy (degenerative brain disease).
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use. Website:www.notificaRAM.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Perindopril/Indapamida TecniGen tablets
The active principles are perindopril and indapamida. Each tablet contains 4 mg of perindopril terbutilaminate salt, equivalent to 3,338 mg of perindopril; and 1.25 mg of indapamida.
The other components (excipients) are:
Lactose monohydrate, microcrystalline cellulose, anhydrous colloidal silica, and magnesium stearate.
Appearance of the product and content of the packaging
Perindopril/Indapamida TECNIGEN is presented in the form of white tablets, in capsule shape, with a groove on both sides; engraved with a “-”on both sides of the groove, on one of the faces and smooth on the back.
Each package contains 30 tablets in PA-ALU-PVC/ALU blisters.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
TECNIMEDE ESPAÑA INDUSTRIA FARMACEUTICA, S.A.
Avda. de Bruselas, 13, 3rd D.Edificio América. Polígono Arroyo de la Vega,
28108 Alcobendas, Spain
Responsible for manufacturing:
ATLANTIC PHARMA PRODUÇOES FARMACEUTICAS, S.A.
Rua da Tapada Grande 2
Abrunheira, Sintra - Portugal
or
MEDINFAR MANUFACTURING, S.A.
Parque Industrial Armando Martins Tavares
Rua Outeiro Da Armada, nº 5.
Condeixa-a-Nova, 3150-194. Portugal
Last review date of this leaflet: May 2020
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.